Phase 1 N=17 Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264
Urticaria
Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Part A — 4; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=26 Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
Advanced Solid Tumors · Lymphoma
Primary: Cmax: Maximum Observed Plasma Concentration of Alisertib — 1338.6; 1354.5 nM
Phase 1 N=12 Proellex® Pharmacokinetic Bridging Study II
Healthy
Primary: Cmax of Proellex — 405.5; 426.7; 824.2 ng/mL
Phase 1 N=11 A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Renal Cell Carcinoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLT): Dose Finding Phase — 3 Participants
Phase 1 N=55 A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
Renal Cell Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1 Participants
Phase 1 N=24 A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 1 N=37 A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
Axial Spondyloarthritis (AxSpA) · Non-radiographic Evidence-AxSpA · Ankylosing Spondylitis
Primary: The Plasma Concentration of Certolizumab Pegol (CZP) in the Infant(s) at Birth — NA µg/mL
Phase 1 N=17 Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD
Chronic Obstructive Pulmonary Disease (COPD) · Asthma
Primary: Subjects With ≥1 Treatment-emergent Adverse Event — 2; 3; 2; 2 Participants
Phase 1 N=10 Diagnosing Natriuretic Peptide Deficiency
Healthy · Lean
Primary: Changes in NT-proANP From Baseline to 8 Hours — -0.33 nmol/l
Phase 1 N=24 Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 1770; 1810; 11.3; 11.3 ng/mL
Phase 1 N=58 A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
Ulcerative Colitis
Primary: Safety and Tolerability of SER-287 — 7; 5; 2; 8 Participants
Phase 1 N=30 Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy Volunteers
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 857; 1390 ng/mL
Phase 1 N=17 A Study of LY2881835 in Healthy People and People With Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Clinically Significant Adverse Effects — 0; 0; 1; 0 participants
Phase 1 N=16 CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)
Non-muscle Invasive Bladder Cancer
Primary: Incidence of Dose-limiting Toxicities Treatment-related Adverse Events. — 9; 6 Participants
Phase 1 N=6 Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers
Healthy
Primary: Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) Tmax — 2.57 hr